Keywords: Cancer, Spectroscopy, DIPG, Pediatrics, NMR
Motivation: There is a need for developing next generation of clinical trials by targeting selective pathways in diffuse intrinsic pontine glioma (DIPG).
Goal(s): We explore the impact of Vehicle (DMSO), Paxalisib, BAY-876, and their combination in patient-derived SJ-DIPGX7 cell line to evaluate their potential as a therapeutic strategy for patients with DIPG.
Approach: 2H-NMR spectra were longitudinally obtained in a cell suspension. We calculated the lactate flux turnover, which was validated using 100-run Monte-Carlo simulation. This outcome was further confirmed by conducting a glycolysis stress test.
Results: The combined therapy (Paxalisib + BAY-876) holds potential for enhancing its therapeutic effectiveness against DIPGs.
Impact: This study paves the way for future in-vitro and in-vivo studies to be conducted for monitoring efficacy of targeted therapeutic combination for DIPG.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords